Access insights from Real-World Evidence in Ophthalmology

Achieve your goals faster with more disease insights in Ophthalmology including Geographic Atrophy, Neovascular Age-related Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema and Inherited Retinal Diseases

By unlocking the full potential of real world data with enriched insights into disease biomarkers, patient populations and treatment trends, we strive to change the way Pharma and Life Sciences tackle strategic decisions in development to clinical research to commercialization.

225K+

High-quality patient records with insights into clinical factors and disease biomarkers to date

10+

Algorithms for retinal layer segmentation, fluid analysis, disease biomarkers and prediction analysis

30+

Peer-reviewed publications on using our models in real world evidence generation

Benefits of our Real World Evidence Insights
across the entire Pharma value chain

Clinical Development

Identify unmet needs to design better research
Improve trial design with specific inclusion and exclusion criteria
Optimize patient selection based on biomarkers influencing disease outcomes

HEOR

Demonstrate value to payers
Compare study data with real world outcomes
Enable value-based pricing

Commercialization

Improve product positioning and messaging
Gain better market knowledge, treatment trends and factors influencing decisions to treatment
Design patient services and education

Why choose our Real-World Evidence Data packages?

We are bringing together data, analytical tools and support to help your company achieve their goals,
faster and with more disease insights than ever before.

Collaborating with top-notch clinical networks globally

RetinAI collaborates with large-scale clinical networks dedicated to delivering exceptional care to their patients. As a result, RetinAI accesses regulatory-grade real world data through partnerships to generate quality-driven real world evidence.

In 2023, RetinAI partnered with Retina Consultants of America,
the largest U.S. retina provider,
to create insights for advancing healthcare in Ophthalmology.

Value across the Ophthalmology product lifecycle

RetinAI’s customized real-world evidence solutions can shorten timelines, minimize risks in development, inform study design and identify target patients.

Pharma decision makers in research, development and commercial rely on real world evidence to improve and enhance their data decision workflow.

Translating real world data to actionable insights for decisions

Our team of data and bio statistician experts integrate best-in-class data management practices, advanced analytics like AI and machine-learning, and comply with the highest measures for data security and privacy, to ensure the highest quality standards in RWE generation needed for decisions, at-scale.

RetinAI’s Discovery platform is 510K-cleared, MDR-certified and complies with HIPAA, GDPR and PIPEDA.

Get in touch!

Tell us more about your real-world evidence goals

*Disclaimer

RetinAI Discovery® platform, RetinAI OCT Atlas® and Macula Biomarkers, as well as LuxIA^® (Diabetic Retinopathy Screening model) are CE-marked medical devices in accordance with the Medical Devices Regulation (EU) 2017/745 (CE2797). RetinAI Discovery® platform is also a medical device cleared for clinical use by the FDA. The AI modules for biomarkers, fluid, and layer segmentation and quantification in retinal pathologies are designated as Research Use Only (RUO) in the USA. Please be advised that these tools are not intended to replace professional medical advice, diagnosis, or treatment. We do not warrant or guarantee the clinical accuracy, completeness, or usefulness of any content provided by RUO products. For more information, please read our Privacy Notice (https://www.retinai.com/privacy-policy) and Data Processing Agreement (https://www.retinai.com/data-processing-agreement).

RetinAI Discovery® and RetinAI® are trademarks of Ikerian AG.

‍

Sign Up And Receive Our Latest Promotions!